1. Home
  2. SLVM vs IOVA Comparison

SLVM vs IOVA Comparison

Compare SLVM & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

HOLD

Current Price

$38.58

Market Cap

1.7B

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$4.97

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLVM
IOVA
Founded
1898
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
SLVM
IOVA
Price
$38.58
$4.97
Analyst Decision
Strong Buy
Buy
Analyst Count
3
10
Target Price
$54.00
$9.00
AVG Volume (30 Days)
312.4K
13.6M
Earning Date
05-08-2026
05-07-2026
Dividend Yield
4.15%
N/A
EPS Growth
N/A
14.84
EPS
N/A
N/A
Revenue
$3,351,000,000.00
N/A
Revenue This Year
$0.93
$47.74
Revenue Next Year
$1.54
$40.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.53
$1.76
52 Week High
$56.80
$5.63

Technical Indicators

Market Signals
Indicator
SLVM
IOVA
Relative Strength Index (RSI) 47.08 62.80
Support Level $36.87 $2.08
Resistance Level $43.60 $5.63
Average True Range (ATR) 1.48 0.39
MACD 0.04 0.05
Stochastic Oscillator 43.81 80.29

Price Performance

Historical Comparison
SLVM
IOVA

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: